On Wednesday, in the course of current trade, Shares of Staples, Inc. (NASDAQ:SPLS), climbed 2.05%, and is now trading at $13.97.
Staples declared that it funded 214 local classroom projects in the Boston, Cambridge and Metrowest communities, as part of its recent $10 million pledge to Think it Up, a new national initiative of the Entertainment Industry Foundation (EIF) that seeks to inaugurate a new movement in support of students, teachers and schools, creating a culture of excitement about learning everywhere in America. This fall, Think It Up, in partnership with DonorsChoose.org, will launch a platform to fund student-powered, teacher-led learning projects in classrooms across the country.
Red Sox Pitcher and Think It Up ambassador Joe Kelly attended the declarement in support of Boston’s students and teachers. “It’s great knowing this generous donation will assist make meaningful learning projects happen in classrooms throughout the Boston area, thanks to Think It Up, DonorsChoose.org, and Staples’ commitment to supporting students,” Kelly said.
Staples, Inc., together with its auxiliaries, operates office products superstores. It operates through three segments: North American Stores & Online, North American Commercial, and International Operations.
During Morning trade, Shares of The Medicines Company (NASDAQ:MDCO), dipped -1.89%, and is now trading at $40.22.
The Medicines Company (MDCO) recently declared that The New England Journal of Medicine (NEJM) has published results from the antithrombin program of the MATRIX trial, a large international, open label, multicenter clinical trial comparing the Company’s anti-thrombotic agent Angiomax®/ Angiox® (bivalirudin) against heparin in 7,213 acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The results were presented recently at a Hot Line Session of ESC Congress 2015 held in London. MATRIX – or Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX – showed that Angiomax®/Angiox was associated with similar rates of the primary outcome of composite major ischemic and net adverse events contrast with heparin, but with significantly lower rates of the secondary outcomes of death and major bleeding. The results of the MATRIX access site program comparing femoral to radial access in 8404 ACS patients were published earlier this year in The Lancet.
“The MATRIX investigators addressed two critical questions in interventional ACS administration, namely choice of anti-thrombotic treatment and vascular access site selection,” said Efthymios N. Deliargyris, MD, Vice President, Global Medical Director, Interventional Cardiology for The Medicines Company. “The reductions in mortality and major bleeding associated with Angiox/Angiomax in this high risk ACS population are compriseent with the extensive body of evidence from multiple, large multicenter clinical trials over the past two decades.”
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Finally, Hancock Holding Company (NASDAQ:HBHC), gained 1.06% Wednesday.
Hancock Holding Company declared that the company’s board of directors has authorized a new common stock buyback program for up to 5%, or about 3.9 million shares, of the company’s outstanding common stock. The shares may be repurchased in the open market or in privately negotiated transactions from time to time, depending upon market conditions and other factors, and in accordance with applicable regulations of the Securities and Exchange Commission. The buyback program will expire September 30, 2016. The buyback program was approved during the August meeting of the company’s board of directors.
Hancock Holding Company operates as the bank holding company for Whitney Bank that provides a range of community banking services to commercial, small business, and retail customers. The company offers various deposit products, counting noninterest-bearing demand deposits, interest-bearing transaction accounts, savings accounts, money market deposit accounts, and time deposit accounts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
